Nathan C. Nussbaum - Concepedia

Author

Nathan C. Nussbaum

Also Known As

N Nussbaum, N.C. Nussbaum, Nathan C Nussbaum, Nathan C. Nussbaum, Nathan Coleman Nussbaum, Nathan Nussbaum, Nussbaum, Nathan

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Flatiron Health (United States)New York University Yale University Dana-Farber Cancer Institute Duke Medical Center

About

Nathan C. Nussbaum is an author at Flatiron Health (United States) specializing in oncology, radiation oncology, and biostatistics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	31
2	Public Health	2	2	213
3	Biostatistics	2	2	216
4	Engineering	1	1	199
5	Health Sciences	1	1	17

Nathan C. Nussbaum

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database Gaurav Singal, Peter G. Miller, Vineeta Agarwala, JAMA	2019	541
Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research Benjamin Birnbaum, Nathan C. Nussbaum, Katharina Seidl-Rathkopf, arXiv (Cornell University) EngineeringMachine LearningPatient SelectionCancer RegistrationOncology Research	2020	199
Validation analysis of a composite <scp>real‐world</scp> mortality endpoint for patients with cancer in the <scp>United States</scp> Qianyi Zhang, Anala Gossai, Shirley Monroe, Health Services Research	2021	162
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting Carolyn J. Presley, Daiwei Tang, Pamela R. Soulos, JAMA	2018	132
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials Jeremy O’Connor, Kristen L. Fessele, Jean Steiner, JAMA Oncology	2018	104
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval Sean Khozin, Amy P. Abernethy, Nathan C. Nussbaum, The Oncologist	2018	96
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer Alexander Liede, Rohini K. Hernandez, Sally Wade, OncoImmunology	2018	73
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC Xinran Ma, Lawrence Bellomo, Kelly Magee, Advances in Therapy	2021	44
Validation of diagnosis codes to identify side of colon in an electronic health record registry Patricia Luhn, Deborah Kuk, Gillis Carrigan, BMC Medical Research Methodology	2019	29
Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types Aracelis Z. Torres, Nathan C. Nussbaum, Christina M. Parrinello, Advances in Therapy	2022	23

Page 1